This is less comforting than it sounds, because the usual method for doing a safety analysis is to include all the deaths that occurred in patients who were assigned to take a drug, not just those that are clearly linked to a treatment, in order to avoid missing anything.

FORBES: Pfizer's Key Drug Walks A Tightrope